Blocking PD‐L2 with different clones and depleting RGMb+ cells showed that only employing an antibody that specifically inhibits PD‐L2/RGMb interaction can disrupt tumor anti‐PD‐L1 resistance in germ‐free mice. The gene discussed is PDCD1LG2; the disease is neoplasm.